Skip to main content

Table 4 Comparison of models among team A, B,C in the BMMR2 challenge and ours

From: Early prediction of neoadjuvant therapy response in breast cancer using MRI-based neural networks: data from the ACRIN 6698 trial and a prospective Chinese cohort

 

Prediction Model

Sequence Used

Timepoint Used

Clinical Feature

Was Model Tested Using Other Data?

Model Performance

Team A

Logistic regression

SER map and kinetic maps from DCE image

Pre-NAT and early-NAT

HR and HER2

No

ACRIN 6698 test: 0.840 (95%CI: 0.748–0.932)

Team B

XGBoost, Random forest, Logistic regression

DCE image, SER map, PE map, DW image

Pre-NAT, early-NAT, and mid-NAT

Age, Race, Lesion Type, SBR Tumor Grade, MRI Longest Diameter, HR and HER2

No

ACRIN 6698 test: 0.838 (95%CI: 0.748–0,928)

Team C

Logistic regression

DW image

early-NAT,

MRI Longest Diameter, HR and HER2

No

ACRIN 6698 test: 0.803 (95%CI: 0.702–0.904)

MESN

Neural networks

DCE image, DW image, and ADC image

Pre-NAT and early-NAT

None

Yes

ACRIN 6698 test: 0.860 (95%CI: 0.757–0.939)

External test: 0.804 (95%CI: 0.752–0.864)

MESN-C

Neural networks, Logistic regression

DCE image, DW image, and ADC image

Pre-NAT and early-NAT

HR and HER2

Yes

ACRIN 6698 test: 0.903 (95%CI: 0.815– 0.965)

External Test: 0.861 (95%CI: 0.811–0.906)

  1. MESN: MRI-based enhanced self-attention network; MESN-C: model built using the signature of MESN and clinicopathological characteristics
  2. DCE = dynamic contrast-enhanced, SER = signal enhancement ratio; DW = diffusion-weighted, HR = hormone receptor, HER2 = human epidermal growth receptor 2